Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Ascorbic Acid in Recurrent High Grade Glioma
NCT02833701Phase 1Terminated
- Sponsor
- University of Nebraska
- Start
- Mar 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ascorbic acid in high-grade glioma (HGG) and glioblastoma (GBM), sponsored by University of Nebraska. Primary endpoint: Frequency of occurrence of overall toxicity at 52 weeks. Started Mar 2016; status: terminated.
02
Drugs
ascorbic acid
03
Conditions
high-grade glioma (HGG)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02833701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833701.